Prof. Domenica Lorusso | Oncologia | Excellence in Research

Humanitas, Italy

Author Profile

Early Academic Pursuits:

Dr. Domenica Lorusso embarked on her academic journey, which has now spanned over two decades, with a focus on gynecological oncology research. Her early academic achievements include a commitment to women's health and a strong foundation in medicine.

Professional Endeavors:

Throughout her illustrious career, Dr. Lorusso has held significant positions in renowned institutions. From January 2019 to February 2020, she contributed to the field as an Associate Professor at "Università Cattolica del Sacro Cuore" in Rome, Italy. Subsequently, she joined the "Fondazione Policlinico Universitario A Gemelli IRCCS" in Rome, Italy, from March 2020 to September 2023, where she served as the Associate Medical Director and Head of various units focused on Clinical Research Development. Her dedication led to her appointment as a Full Professor at Humanitas University in Milan from October 2023, and presently, she holds the prestigious position of Head of Gynecologic Oncology Unit at Humanitas San Pio X Hospital.

Contributions and Research Focus:

Dr. Lorusso has made invaluable contributions to gynecological oncology research, overseeing around 108 phase I-IV clinical trials in the last decade. As the Principal Investigator of 30 active studies, she plays a pivotal role in advancing the understanding and treatment of gynecological malignancies. Her leadership extends to the Clinical Trials Committee of the MITO Group, where she collaborates with over 180 Italian centers. Dr. Lorusso is a crucial member of the Gynaecological Cancer Intergroup, promoting high-quality clinical trials internationally. As a Council Member of the European Society of Gynecological Oncology (ESGO) and an active participant in the European Network of Gynaecological Oncological Trial groups (ENGOT), she contributes to shaping the future of gynecologic cancer research globally.

Accolades and Recognition:

Dr. Lorusso's impactful contributions have been acknowledged with numerous accolades. Notably, she received the Shri Om Prakash Sharma Young Scientist Award in 2021 from the Indian Academy of Biomedical Sciences. Her international recognition includes being elected as a Member of the American Association for Clinical Chemistry, USA, in 2022, and as an Associate Member of the Royal Society of Biology, United Kingdom, in 2020.

Impact and Influence:

Dr. Lorusso's influence extends beyond her individual research pursuits. As the Chair of the Gynecological Cancer Academy, she actively promotes networking and mentorship for future leaders in the treatment of gynecologic cancers in Europe.

Legacy and Future Contributions:

Dr. Domenica Lorusso's legacy is characterized by her unwavering commitment to clinical research, international collaboration, and advancements in the field of gynecological oncology. Her future contributions are anticipated to further elevate the standards of care for women with gynecological cancers and continue inspiring the next generation of researchers and clinicians.


A total of  2298 citations for his publications, demonstrating the impact and recognition of his research within the academic community.

  • Citations            17428
  • h-index               55
  • Document         389

Notable Publications 

Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group

Maintenance therapy for newly and recurrent epithelial ovarian cancer: Current therapies and future perspectives

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab

Pembrolizumab or Placebo Plus Chemotherapy with or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial

Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results from the innovaTV 205/GOG-3024/ENGOT-cx8 Study

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial

Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspective


Domenica Lorusso | Oncologia | Excellence in Research

You May Also Like